ICAT Competitors Are Slow to Step Up to Plate: Amersham Waits on Deck | GenomeWeb

Most proteomics researchers and industry watchers are probably familiar with ICAT, a tagging technology developed by Ruedi Aebersold’s former laboratory at the University of Washington. By extension, many in the field are probably familiar with the typical complaints — warranted or not — associated with the ICAT reagent technology: It requires a steep learning curve, its affinity selection criteria are arbitrary, and perhaps most importantly, its cost is high.

So where are the alternatives?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.